life inspliirvee live life fully bless jeff julian annual reporton cover jeff julian jeff story patient story share annual report depict individual patient response medicine investigational compound representative patient response addition guarantee potential drug indication development receive regulatory approval bristolmyer squibb annual report strengthen platform creating value recognize responsibility shareholder build longterm sustainable growth innovation make difference today tomorrow giovanni caforio chief executive officer researcher tiffany kuo work generation immunotherapy medicinesin organization world work continue drive unwavering commitment people center patient familie giovanni caforio chief executive officer focus future continue make difference today tomorrow advance biopharma strategy initiate important operating model evolution aim organization world focus resource important work continue drive unwavere priority business commitment people center year strengthen thing patient family platform create value recognize reason focus transformational responsibility shareholder build longterm medicine reason work hard sustainable growth innovation fast deliver result troper launna bbiuqs sreymlotsirb shareholders important year bristolmyer squibb deliver strong operational financial result expand indication market performance inhibitor opdivo advance eliquis leadership prevention stroke patient atrial fibrillation advance broad deep portfolio pipeline opportunitie immunooncology core specialty therapeutic area cardiovascular fibrosis immunoscience continue work underserved community healthcare accessible need global sale region united states rest world include japan europethese accomplishment represent late string impressive leadership milestone achieve eliquis deliver today year include new indication head neck cancer respect overall operating achieve late year performance outstanding year bladder cancer achieve early exceed budget target deliv see opdivo grow outside ere billion revenue growth significant regulatory approval precede year european union japan doubledigit growth number key market portfolio immunooncology key total prescription indication growth driver strong result result strong operating specialty include anticoagulant eliquis novel anti formance achieve gaap ep coagulant noacs deliver billion sale nongaap eps newtobrand increase previous year eliquis represent growth prescription lead oral anticoagulant indication previous year respectively specialtie globally stroke prevention patient oral anticoagulant success drive atrial fibrillation include warfarin strength immunooncology establish leadership eliquis reach portfolio revenue nearly billion cardiology term number total hospitalinstitutional sale noacs opdivo sale reach billion result prescription surpass warfarin strong uptake tumor type longtime standard care additionally yervoy sale start grow good progress overall global market adoption combina market include primary care yearover year growth tion regimen melanoma physician indication tackle hardesttotreat cancer orencia sprycel perform approve country challenge see firsthand experience doubledigit worldwide august negative outcome growth billion billion checkmate opdivo monotherapy sale respectively clinical trial line lung cancer estimate company partner ono integrate important lesson learn secured important patent litigation trial broad development settlement sign global license program lung cancer believe agreement settle patentinfringe medicine continue play ment litigation relate merck people important role improve treatment antibody keytruda pembrolizumab treat outcome deadly disease settlement critical milestone eliquis worldwide generally broaden bristolmyer squibb protect launch label opdivo approve intellectual property right early indication tumor innovator science key type unprecedented accomplishment mechanism immunooncology bristolmyers squibb annual report deliver number billion revenue prove transformational impact cancer care continue assert intellectual property right important field defend scientific discovery deliver tomorrow growth year focus effort build future clear work develop enhance promise pipeline transformational medicine end year start datum wave pipeline immunooncology new asset potentially enter registrational study opdivo addition expect dozen datum readout span billion multiple tumor type broaden label opdivo yervoy couple year eliquis billion lung cancer remain priority bristolmyer squibb important progress study combina orencia tion therapie core strategy fact billion ongoing phase iii combination program sprycel address urgent need improve treatment option billion patient lung cancer advance early pipeline cardiovascular hepatitis franchise immunoscience fibrosis expect important billion datum readout begin program address win yervoy area high unmet medical need heart failure lupus immunooncology billion nonalcoholic steatohepatitis nash firstinclass molecule potential bestinclass recognize importance acquire innovation externally important year new compound business development bristolmyers squibb business clinical development development activity continue enhance key disease billion area focus span partnership academia invest trial biotech large company acquire cormorant pharmaceutical broaden company oncology pipeline focus tumor microenvironment padlock therapeutic expand company immunoscience tumor type pipeline sign license agreement nitto denko troper launna bbiuqs sreymlotsirb jeff julian competitor coach cancer survivor head coach rise bowl aquatic ready say ready year eighttime dear friend leave family basically keep allamerican university southern repeating family love one california usc champion swimmer leave son leave adolescent jeff julian wife know takes succeed doctor give jeff wife world early january rock today kristine little reason hope announcement social medium dear oncologist university california friends family love one world los angeles medical center mention clinical trial rock today combination therapy new immunotherapy drug ipilimumab nivolumab study combination doctor give diagnosis stage therapy treatment lung cancer continue lung cancer jeff enrol week treatment nag pain scan show tumor shrink significantly previous summer jeff feel right continue shrink substantially small lot athlete water lot potential original size lot goal shoot recall start feel pain inspire july jeff return alma mater name xray reveal large mass jeff left lung subsequent usc trojans men womens assistant coach scan reveal extensive metastasis prognosis continue coach son aspire olympian month say jeff hard say sit trenton yearold son talk live life inspire live life diagnosis fully bless jeff say bristolmyers squibb annual report target sirna therapy advance nash psioxus therapeutic armed oncolytic virus address solid tumor collaboration enterome focus microbiomederived biomarkers drug alan anderson texas childrens hospital examine cancer patient botswana target developed therapeutic cancer global hope address childhood cancer order ensure resource apply import blood disorder africa ant opportunity company initiate evolution operating model strengthen ability seize child diagnose lifethreatening opportunity increasingly challenging environment disease cancer parent cling hope child survive hope deliver underserved community disproportionate depend live year continue build execute africa child develop program help ensure patient access health cancer year vast majority die care include medicine bristolmyer little access diagnostic squibb foundation promote health equity well treatment service stark contrast health outcome people world highincome country percent patient assistance program provide medicine pediatric cancer patient survive patient financial challenge lead bristolmyer squibb foundation take commitment access focus secure future program global population need global scope include hope hematologyoncology pediatric excellence hiv cancer africa hepatitis asia initiative address lack diagnosis treat include cancer care vulnerable population ment care pediatric hematologyoncology mental health care veteran southern eastern africa commitment include program include texas children cancer help patient need temporary help pay hematology center baylor college medication medicine international pediatric aid initiative commitment good citizenship extend texas childrens hospital bristolmyers squibb initiative continue work united foundation partner government nation global compact green activi botswana malawi uganda develop com tie bristolmyer squibb site promote sustainability prehensive treatment network provide financial inkind resource program provide disaster relief support affect population haiti ecuador japan join white house combine grant million moonshot initiative share goal accelerate new group work year help treatment eventually find cure cancer create innovative pediatric hematologyoncology treatment network help build longterm place exciting new initiative provide capacity treat dramatically improve cancer care child subsaharan africa formally prognosis thousand child blood dis order cancer southern eastern africa troper launna bbiuqs sreymlotsirb jones find purpose cancer diagnosis jones get fit tuxedo nearly year battle hodgkin wedding notice bow tie thought lymphoma treatment cooperate oncologist tell life get ready month live well tie straight recall affair order tell time adjust tie begin come wife grim news get determine slightly slanted end countless hour research notice lump neck internet kts perseverance lead thought pull muscle clinical trial nivolumab gym day visit nearby hospital physician examine lump continue push found tell biopsy soon get home recall hammer fight honeymoon get clinical trial shortly celebrate marriage wife kristine soon start feel well health improve test reveal hodgkin lymphoma nearly year later kts late test detect cancer kristine enjoy quality time think life get ready begin come take walk day follow artistic end say decade juggle family passion freelance photographer life work chemotherapy treatment ultimately heartbreake news cancer recur fill new sense purpose good result shortly stop treatment know people fight cancer cancer start grow say life help find clinical trial say purpose delaware option try bristolmyer squibb annual report achievement selection award recognition launch global hope look forward firstofitskind pediatric hematology rank look ahead excite oncology treatment network corporate responsibility tremendous opportunity magazine list design develop capacity advance science continue good corporate citizen infrastructure treat dramatically make difference live consecutive year improve prognosis outcome patient family thousand child cancer important work deliver southern eastern africa longterm value shareholder strengthen company appointment thomas lynch recognize forbe chief scientific officer culture america good employer important step evolution employee commit past year contin mission discover develop company transition phase deliver innovative medicine ued focus people growth tom bring unique perspec help patient prevail possible extraordinary tive business deep disease colleague world experience clinical researcher leader large research center practice place increase priority physician fortunate making sure experience lead organization bristolmyer squibb employee honor national gay engage challenging rewarding building progress lesbian chamber commerce increase focus diversity position navigate collaboration create powerfully inclusive work increase complexity competi partner national business tiveness industry include inclusion consortium experience launch new global bestoftheb company people business resource group important conversation pricing access continue pbrg evolution draw energy vision diversity base employee resource group workforce discover develop leverage employee business deliver transformational medicine insight diverse perspective continue advanced workplace initiative work mother sure patient make significant physical change good company regardless circumstance consecutive year building office create access quality healthcare company list energize collaborative work company recognize environment onand nearsite childcare option benefit eligibility bristolmyer squibb people competitive advantage continue giovanni caforio chief executive officer celebrate strengthen fact march troper launna bbiuqs sreymlotsirb believe strength science good people business position continue deliver innovation difference live patient lamberto andreotti chairman message chairman board retire board director nearly past year giovanni continue evolve year company reflect company confident position significant transformation bristolmyer squibb longterm growth today highly focus undergone leading biopharma company know transformational medicine core therapeutic area innovation focus patient oncology cardiovascular fibrosis immunoscience company know lead scientific discovery inno innovationbase industry unique challenge vative medicine focus challenging disease risk experience recent past continue evolve change today know believe strength science well sustain platform longterm value creation people business position continue deliver join bristolmyer squibb want innovation make difference live patient work company make difference people well example addition live particularly struggle cancer decade thomas lynch company new chief scientific later give extraordinary opportunity lead officer experience focus patient career company company level help make right choice lead organization reach potential closing want welcome new chief executive officer pivotal exciting director recently join company board time bristolmyer squibb bob bertolini matt emmens ted samuel way period adjustment midst bring company important experience skill biopharma transformation face unprecedented strengthen complement board challenge opportunity transform bristol myers squibb well compete everchange bristolmyer squibb continue evolve grow external environment focus patient people continue set apart proud company question rise challenge seize excited future opportunity step ceo bristolmyer squibb widely recognize pioneer thank promise field immunooncology increasingly diversify portfolio innovative medicine lamberto andreotti chairman deliver strong shareholder return march bristolmyers squibb annual report bristolmyer squibb development pipeline oncology phase phase phase iii approve indication glypican adc opdivo opdivo opdivo hepatocellular carcinoma nonhodgkin lymphoma adjuvant melanoma previously treat follicular lymphoma metastatic melanoma antitigit line small cell solid tumor nonhodgkin lymphoma lung cancer line braf wildtype diffuse large bcell metastatic melanoma antigitr unresectable nonsmall lymphoma solid tumor cell lung cancer melanoma braf status msi colon cabiralizumab line head neck previously treat metastatic solid tumor ovarian squamous nonsmall cell line gastric lung cancer anticd line hepatocellular line glioblastoma solid tumor carcinoma previously treat metastatic line glioblastoma nonsquamous nonsmall cell antiox cns lymphoma lung cancer solid tumor line hepatocellular antilag opdivo carcinoma previously treat advanced antilag solid tumor renal cell carcinoma solid tumor lirilumab adjuvant bladder hematologic malignancy advanced hodgkin hematologic malignancy line esophageal lymphoma ido inhibitor urelumab opdivo adjuvant esophageal solid tumor previously treat metastatic solid tumor gastroesophageal head neck cancer mesothelinadc hematologic malignancy opdivo yervoy solid tumor previously treat metastatic antifucosyl line nonsmall urothelial carcinoma humaxil small cell lung cancer cell lung cancer solid tumor opdivo yervoy empliciti line small cell antiher line multiple myeloma lung cancer braf wildtype metastatic melanoma breast cancer pomalidomide combo line renal cell melanoma braf status bet inhibitor yervoy carcinoma solid tumor adolescent melanoma yervoy line head neck metastatic melanoma ulocuplumab sprycel line gastric hematologic malignancy pediatric adjuvant melanoma line esophageal lirilumab empliciti solid tumor line mesothelioma relapsedrefractory multiple myeloma revlimid combo lirilumab empliciti opdivo empliciti multiple myeloma multiple myeloma sprycel line chronic urelumab empliciti empliciti myelogenous leukemia multiple myeloma line multiple myeloma revlimid combo refractory chronic opdivo solid tumor prostvac myelogenous leukemia hematologic malignancy metastatic castration resistant prostate cancer opdivo yervoy solid tumor opdivo pediatric note pipeline exclude clinical collaboration evelopment partnership empliciti abbvie sprycel otsuka opdivo yervoy ono pharmaceutical collaboration ono include early stage compound prostvac bavarian nordic lirilumab innate pharma antiher fstar alpha ltd cabiralizumab prime therapeutic eliquis pfizer galectin inhibitor galecto biotech pentraxin promedior hsp nitto denko corporation trial explore combination partnerrun study option right troper launna bbiuqs sreymlotsirb bristolmyers squibb development pipeline immunoscience phase phase phase iii approve indication tyk inhibitor lulizumab orencia orencia autoimmune disease lupus lupus nephritis rheumatoid arthritis intravenous pdl inhibitor btk inhibitor psoriatic arthritis autoimmune disease rheumatoid arthritis rheumatoid arthritis sjogren syndrome subcutaneous btk max anticdl nulojix rheumatoid arthritis autoimmune disease switch cni rheumatoid arthritis auto injector tyk inhibitor renal transplant autoimmune disease psoriasis juvenile idiopathic arthritis antiip early rheumatoid arthritis ulcerative colitis nulojix antipdl novo renal transplant sepsis opdivo sepsis cardiovascular phase phase phase iii approve indication factor xia inhibitor nitroxyl donor eliquis eliquis vte prevention thrombosis heart failure pediatric vte treatment orthopedic surgery par antagonist stroke prevention thrombosisstroke atrial fibrillation vte treatment fibrotic disease genetically define disease phase phase phase galectin inhibtor lpa antagonist antimyostatin idiopathic fibrosis duchenne muscular dystrophy pulmonary fibrosis pegfgf antietau pegfgf fibrosis progressive supranuclear palsy fibrosis pentraxin hsp myelofibrosis fibrosis idiopathic pulmonary fibrosis datum january approve fda february bristolmyers squibb annual report dagmar enjoy life simple pleasure dagmar vibrant dynamic receive news cancer personality share cancer equal death return bring live studio audience cohost emotion diagnosis cancer equals fight successful weekday talk time dagmar know con raymond dagmar question ask fight puerto rico afraid know survival dagmar experience way hope way persistent soreness throat attribute forward survive say dagmar line work time dagmar know listen body doctor biopsy discover surgery lung dagmar oncologist recommend head neck cancer opdivo dagmar begin treatment june return routine way life include reprising role dagmar remain away camera month cohost fda approve opdivo receive chemotherapy radiation pain worry treatment patient recurrent metastatic unknown dagmar remain hopeful focused time squamous cell carcinoma head neck disease life simple pleasure especially walk beach progression platinumbase therapy diagnose cancer appreciation little moment life walk beach hearing today dagmar use experience platform encourage wave feel salt water put foot cancer important sand beautiful moment say dagmar thing patient hold belief possible dagmar return work think bad door open right scan show cancer tell door metastasize dagmar lung say dagmar troper launna bbiuqs sreymlotsirb bristolmyers squibb financial report management discussion analysis financial condition result operation quantitative qualitative disclosure market risk consolidated financial statement note consolidated financial statement report management control procedure report independent register public accounting firm performance graph fiveyear financial summary summary abbreviate term fin ccindd pmbristolmyer squibb management discussion analysis financial condition result operation executive summary bristolmyers squibb company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end annual report term document receive approval new medicine additional indication formulation currently market medicine major market japan announce multiple regulatory milestone achievement opdivo encounter significant setback firstline lung cancer announcement negative result checkmate announce pursue accelerate regulatory pathway opdivoyervoy combination therapy firstline lung cancer pursue broad program firstline lung cancer encompass combination opdivoyervoy opdivo chemotherapy opdivo combine yervoy chemotherapy commit investigate opdivo combination yervoy anticancer agent tumor type continue believe breadth depth portfolio position future new compound clinical development trial different tumor type october announce evolution operating model discuss strategy revenue increase result high opdivo eliquis orencia product sale impact partially offset expiration commercialization right abilify transfer erbitux right north america increase competition reyataz sustiva baraclude certain market increase gaap eps high revenue divestiture gain royalty low license asset acquisition charge partially offset high eliquis profit sharing opdivo relate expense tax impact specify item earning mix contribute change effective tax rate adjust divestiture gain license asset acquisition charge specify item nongaap eps increase highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision income taxis effective tax rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure annual report significant product pipeline approval follow summary significant approval receive product date approval jmhlw manufacturing marketing approval treatment relapse refractory december chl receive alliance partner ono approval treatment adult patient relapse refractory chl asct november treatment brentuximab vedotin fda approval treatment patient scchn disease progression november platinumbase therapy jmhlw manufacturing marketing approval treatment unresectable opdivo august metastatic rcc receive alliance partner ono fda approval treatment patient chl relapse progress autohsct posttransplantation brentuximab vedotin april approval treatment previously treat rcc april approval treatment previously treat patient metastatic nsq nsclc jmhlw manufacturing marketing approval treatment previously untreated february unresectable melanoma approval treatment unresectable metastatic melanoma regardless braf opdivo mutational status yervoy fda expand use treatment previously untreated unresectable metastatic january melanoma regardless braf mutational status jmhlw manufacturing marketing approval combination revlimid september dexamethasone treatment multiple myeloma empliciti approval treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy approval combination mtx treatment highly active progressive september disease adult patient previously treat mtx announce commercial launch orencia clickject autoinjector new self orencia july administer autoinjector adult moderate severe announce commercial launch japan orencia clickject autoinjector adult moderate severe jmhlw manufacturing marketing approval ximency combination tablet december contain daclatasvir asunaprevir beclabuvir treatment hcv genotype hepatitis fda approval daklinza use sofosbuvir treatment chronic hcv february franchise genotype additional patient population approval daklinza use sofosbuvir treatment chronic hcv january new patient population approval reyataz oral powder indicate hivinfecte child month reyataz june optimize reyataz capsule pediatric dose recommendation refer product pipeline development development market product latestage pipeline strategy focus specialty biopharmaceutical company discover develop deliver transformational medicine address unmet medical need strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry strategic priority drive business performance continue build strong franchise maintain diversified portfolio outside continue discipline approach capital allocation include establish partnership collaboration essential component successfully deliver transformational medicine patient bristolmyer squibb develop new medicine follow core therapeutic area oncology include immunoscience cardiovascular fibrotic disease gdd continue invest new study monotherapy combination therapy new molecule mechanism action deliver promise new treatment option patient lung cancer quickly possible continue priority company continue invest significantly deep pipeline innovative medicine cover broad array cancer enter collaboration agreement research develop opdivo approve investigational oncology agent combination regimen include yervoy remain focused wellresource firstline lung development program continuously look way strengthen broad portfolio bring forward new treatment cancer continue strengthen early stage portfolio immunoscience cardiovascular fibrotic disease internally partnership diverse group company academic institution new expand research activity believe internal external focus differentiate contribute transformation portfolio commercial model continue evolve market product portfolio grow manner consistent overall strategy continue drive growth opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent opdivo yervoy build continue success remain strongly commit eliquis orencia sprycel commercial infrastructure uniquely leverage potential growth announce plan multiyear evolution operating model focus commercial resource key brand market deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio new operating model enable deliver strategic financial operational flexibility necessary invest high priority look ahead continue implement biopharma strategy drive growth key brand execute product launch invest diverse innovative pipeline include business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition licensing arrangement acquisition licensing transaction allow focus resource growth opportunity drive great longterm value focus follow core therapeutic area oncology include immunoscience cardiovascular fibrotic disease significant transaction enter summarize nitto denko december bms nitto denko enter exclusive worldwide license agreement grant bms right develop commercialize nitto denko investigational sirna molecule target hsp vitamin contain formulation include nitto denko lead asset ndls currently phase study treatment advance liver fibrosis agreement grant bms option receive exclusive license hsp sirnas vitamin contain formulation treatment lung fibrosis organ fibrosis cormorant july bms acquire outstanding share cormorant private pharmaceutical company focus development therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary mechanism action tcell direct antibodie costimulatory molecule padlock april bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patient rheumatoid arthritis padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease portola february bms pfizer enter collaboration license agreement portola develop commercialize investigational agent andexanet alfa japan andexanet alfa design reverse anticoagulant activity factor inhibitor include eliquis bms pfizer responsible development regulatory activity andexanet alfa japan exclusively commercialize agent japan portola retain rights andexanet alfa outside japan responsible manufacturing supply addition transaction bms provide notice termination california institute biomedical research pertain research collaboration agreement development antifibrotic preclinical compound dual therapeutic llc pertain research collaboration agreement development anticancer preclinical compound annual report result operation regional revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period sale increase revenue result high demand opdivo eliquis daklinza partially offset year impact expirationtransfer commercialization right abilify erbitux average net selling price increase approximately chargeback rebate discount refer product revenue commentary additional information increase revenue result launch opdivo daklinza high demand eliquis sprycel partially offset partial year impact expirationtransfer commercialization right abilify erbitux average net selling price increase approximately chargeback rebate discount increase europe revenue result high demand opdivo eliquis partially offset low demand yervoy europe revenue include recognition approximately million previously defer daklinza revenue france decrease europe revenue result unfavorable foreign exchange expiration commercialization right abilify june partially offset launch daklinza certain country quarter high demand eliquis europe revenue impact recognition previously defer daklinza revenue france decrease rest world revenue result increased competition hepatitis franchise japan unfavorable foreign exchange primarily latin america partially offset high demand opdivo eliquis increase rest world revenue result launch daklinza sunvepra dual regimen japan quarter high demand eliquis partially offset unfavorable foreign exchange primarily japan decrease revenue result expiration certain supply arrangement decrease revenue result expirationtransfer certain licensing royalty right refer item financial statementsnote alliance discussion alliance single country outside contribute total revenue japan contribute total revenue bristolmyers squibb grosstonet adjustment recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately million billion billion grosstonet adjustment decrease expiration commercialization right abilify april activity end reserve balance significant category grosstonet adjustment follow rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period return payment foreign currency translation balance december provision relate sale current period prior period return payment foreign currency translation balance december reconciliation gross product sale net product sale significant category grosstonet adjustment follow exclude alliance revenues abilify atripla year end december change dollar million gross product sale grosstonet adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total grosstonet adjustment net product sale change grosstonet adjustment primarily function change sale volume payer channel mix contractual legislative discount rebate grosstonet adjustment increase high rate gross product sale primarily increase mix versus international gross product sale adjustment high chargeback cash discount increase period primarily high eliquis opdivo product sale medicaid medicare rebates increase period primarily high eliquis product sale rebate return discount adjustment increase primarily high worldwide sale eliquis opdivo increase high sale eliquis additional rebate daklinza approximately million amount previously defer france annual report product revenue year end december change dollar million oncology empliciti elotuzumab nonus erbitux cetuximab nonus opdivo nivolumab nonus sprycel dasatinib nonus yervoy ipilimumab nonus cardiovascular eliquis apixaban nonus immunoscience orencia abatacept nonus virology baraclude entecavir nonus hepatitis franchise daclatasvir asunaprevir nonus reyataz atazanavir sulfate franchise nonus sustiva efavirenz franchise nonus neuroscience abilify aripiprazole nonus mature product nonus change excess bristolmyer squibb empliciti humanize monoclonal antibody treatment multiple myeloma empliciti launch december japan september erbitux monoclonal antibody treatment certain type metastatic colorectal cancer scchn bms transfer right erbitux north america lilly october refer item financial statementsnote alliance discussion opdivo fully human monoclonal antibody bind nkt cell approve continue investigate anticancer treatment refer significant product pipeline approval discussion opdivo approval international revenue increase period high demand result rapid commercial acceptance indication include melanoma head neck lung kidney blood cancer expect competition increase sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate revenue increase period high average net selling price demand international revenue increase high demand international revenue decrease unfavorable foreign exchange partially offset high demand experience decline european revenue second half unfavorable epo board appeal decision yervoy monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase high demand result approval adjuvant treatment opdivoyervoy regimen patient metastatic melanoma revenue decrease low demand result introduction product treat patient melanoma include opdivo international revenue decrease low demand result introduction product treat patient melanoma include opdivo international revenue decrease unfavorable foreign exchange eliquis oral factor inhibitor target stroke prevention adult patient nonvalvular atrial fibrillation prevention treatment venous thromboembolic disorder international revenue increase period high demand result increase commercial acceptance novel oral anticoagulant market share gain orencia fusion protein indicate adult patient moderate severe active indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period high average net selling price demand international revenue increase period high demand partially offset unfavorable foreign exchange baraclude oral antiviral agent treatment chronic hepatitis revenue continue decrease period loss exclusivity september international revenue decrease follow loss exclusivity south korea october international revenue decrease unfavorable foreign exchange partially offset high demand certain country hepatitis franchise daklinza nsa replication complex inhibitor sunvepra protease inhibitor daklinza launch july international revenue decrease low demand result increase competition primarily japan international revenue include recognition approximately million previously defer daklinza revenue france international revenue increase high demand follow launch certain country japan quarter subsequent approval international market international revenue expect significantly decline low demand result increase competition annual report reyataz franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir cobicistat combination therapy contain reyataz tybost revenue continue decrease period low demand result increase competition partially offset high average net selling price loss exclusivity reyataz expect december experience high decline revenue future period generic competition international revenue continue decrease period low demand result increase competition unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla revenue continue decrease period low demand result increase competition partially offset high average net selling price loss exclusivity sustiva expect december result termination joint venture agreement gilead reduce revenue international revenue continue decrease period sustiva loss exclusivity europe november abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder commercialization right abilify expire april international revenue decrease period follow expiration commercialization rights june otsuka principal end customer sale certain market mature product include product include lose exclusivity major market diabetes alliance product otc brand royalty revenue revenue decrease favorable impact sale return reserve reduction plavix million revenue decrease primarily diabetes business divestiture february international revenue decrease expiration certain supply arrangement low sale divestiture certain mature product increase competition otc product unfavorable foreign exchange international revenue decrease expirationtransfer certain licensing royalty right diabetes business divestiture unfavorable foreign exchange continue generic erosion estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france efferalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand primarily france support product seasonality perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country saudi arabia extend delivery lead time generally determine month hand estimate inventory level product hand movement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process bristolmyer squibb nonus business significantly direct customer information available direct customer product level inventory correspond outmovement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer party market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative research development incomeexpense total expense change excess cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty processing cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit sharing attribute license product alliance foreign currency hedge settlement gain loss amortization acquire develop technology cost business combination regulatory approval milestone cost product sell typically vary period result product mix volume particularly result royalty profit sharing expense connection alliance change foreign currency price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost cost product sell increase primarily high eliquis profit share million low foreign currency hedge settlement gain high puerto rico excise tax cost product sell remain relatively flat high eliquis profit sharing million offset favorable foreign exchange marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement expense typically vary period new product launch promotional activity marketing sell administrative expense increase high advertising promotion additional sale relate activity support opdivo partially offset low spend virology product favorable foreign exchange marketing selling administrative expense remain relatively flat increase salesrelated activity support eliquis opdivo hepatitis franchise offset favorable foreign exchange million additional expense relate brand prescription drug fee result change irs guideline annual report research development research development activity include discovery research preclinical clinical development drug formulation clinical trial medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense decrease low license asset acquisition charge partially offset acceleration expansion opdivo development program capabilitie low iprd impairment charge research development expense increase high license asset acquisition charge acceleration expansion opdivo development program capability partially offset low iprd impairment charge favorable foreign exchange license asset acquisition charge million billion million include million padlock nitto denko flexus cormorant billion flexus cardioxyl prime million ipierian million milestone pay shareowner flexus commencement phase clinical trial iprd impairment charge million million million include million lpa antagonist million peginterferon lambda accelerate depreciation million million result expect exit certain site accelerate depreciation result reduction estimate useful life relate asset site date expect approximate million refer item financial statementsnote alliance note acquisition divestiture note goodwill intangible asset acquisition licensing arrangement nongaap financial measure specify item information incomeexpense income increase billion high divestiture gain royalty license income less extent low litigation settlement pension debt redemption charge expense decrease million low pension charge partially offset low divestiture gain divestiture gain million million million include certain otc product investigational hiv medicine business mount vernon indiana manufacturing facility erbitux ixempra certain mature otc product business diabete business royalty license income million million million include contingent consideration erbitux diabetes business divestiture include transfer certain future royalty right pertain amylin product sale pension charge million million million include additional pension charge million follow purchase group annuity contract prudential insurance company america provision restructure million million million october company announce evolution operating model drive company continue success near longterm focus investment commercial opportunity key brand market competitive agile organization accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability reflect current future portfolio new operating model enable company deliver strategic financial operational flexibility necessary invest high priority company restructuring charge approximately million expect incur action addition accelerate depreciation impact discuss refer item financial statementsnote acquisition divestiture note incomeexpense note restructuring note pension postretirement benefit plan information bristolmyer squibb income taxis dollar million earning income taxis provision income taxis effective tax rate historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico bms operate favorable tax grant puerto rico schedule expire prior tax impact attribute charge divestiture transaction specify item include additional transfer pricing reserve increase effective tax rate reduce effective tax rate tax benefit attribute charge padlock flexus cormorant flexus cardioxyl ipierian lower nondeductible goodwill allocate business divestiture high valuation allowance attribute capital loss carryforward release impact effective tax rate minimal income taxis attribute diabetes business divestiture gain capital loss deduction sale amylin share tax basis difference result primarily allocate goodwill amylin defer taxis unfavorable earning mix high low tax jurisdiction high foreign tax credit result puerto rico excise tax period impact effective tax rate refer item financial statementsnote income taxis information comprehensive tax reform continues discuss propose include item change corporate tax rate border adjustment tax change tax foreign earning currently uncertain change enact effective date comprehensive tax reform occur financial condition result operation cash flow significantly impact unable determine potential impact time nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include restructuring cost accelerate depreciation impairment property plant equipment intangible asset charge connection acquisition license party intellectual property right divestiture gain loss pension legal contractual settlement charge debt redemption gain loss item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understand underlying financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap annual report specify item follow year end december dollar million cost product solda additional year brand prescription drug fee process standardization implementation cost marketing sell administrative license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment write option adjustment loss debt redemption otherb incomeexpense increase pretax income income taxis item specify tax chargec income taxis increase net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost include million additional year brand prescription drug fee specify tax charge relate transfer pricing matter reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap bristolmyers squibb financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing current portion longterm debt longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment work capital maturity longterm debt management continuously evaluate company capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security example issue senior unsecured note register public offering generating proceed billion redeem repurchase certain note nearly billion refer item financial statementsnote financial instrument fair value measurement detail companys common stock repurchase capacity increase billion october company enter asr agreement repurchase approximately billion common stock february refer item financial statementsnote equity detail dividend payment billion billion dividend decision quarterly basis board director capital expenditure approximately billion million million expect approximately billion million high spending expect result expand biologic manufacturing capability facilityrelate activity example construct new large scale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete marketable security portfolio subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statementsnote financial instrument fair value measurement detail currently separate billion revolving credit facility syndicate lender facility provide customary term condition financial covenant extend october july facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility vote depart june similar company industry certain regulatory trade labor aspect business likely affect time currently believe matter relate financial effect material impact consolidate result operation financial position liquidity sale represent total revenue annual report credit rating bms longterm shortterm credit rating assign moody investor service prime respectively negative longterm credit outlook bms longterm shortterm credit rating assign standard poor respectively stable longterm credit outlook bms longterm shortterm credit rating assign fitch respectively stable longterm credit outlook longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection continue impact long payment term certain biologic product primarily new oncology product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient billion increase cash provide operating activity primarily attributable high operating cash flow attribute increase sale time cash collection payment ordinary course business include winddown abilify alliance lower upfront milestone payment alliance license arrangement approximately million partially offset high income tax payment approximately billion billion decrease cash provide operating activity primarily attributable timing payment alliance partner approximately million particularly active product ingredient supply medicaid rebate abilify high upfront payment new alliance licensing agreement approximately million timing customer collection result primarily high net product sale include extended payment term certain new product factor approximately million partially offset time cash collection payment ordinary course business include item change inventory level particularly relate abilify bristolmyer squibb investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture include royalty sale maturity marketable security billion decrease cash investing activity primarily attributable high net redemption marketable security approximately billion reinvested cash equivalent manage credit interest rate risk low asset acquisition payment approximately million asset acquisition include cormorant padlock flexus cardioxyl high business divestiture proceed approximately million include royalty contingent consideration receive subsequent divestiture divestiture include certain otc product investigational hiv business mount vernon indiana manufacturing facility ixempra mature otc product business partially offset high capital expenditure approximately million billion decrease cash provide investing activity primarily attributable low business divestiture proceed billion divestiture include mount vernon indiana manufacturing facility ixempra mature otc product business diabete business high asset acquisition payment approximately million asset acquisition include flexus cardioxyl ipierian high capital expenditure approximately million partially offset low net purchase marketable security billion financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing million decrease cash financing activity primarily attributable low longterm net debt repayment approximately million high net shortterm borrowing approximately million consist primarily change bank overdraft partially offset repurchase common stock approximately million million increase cash financing activity primarily attributable low net shortterm borrowing approximately million consist primarily change bank overdrafts contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liabilitiesc total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution include pension liability annual report addition commit aggregate billion potential future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical trial latestage milestone billion milestone achieve post phase iii clinical trial payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statementsnote alliance information alliance discussion contractual obligation refer item financial statementsnote income taxis note financial instrument fair value measurementsand note pension postretirement postemployment liabilitie sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain ima pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent addition previously disclose october company reach civil settlement sec allege fcpa violation company agree pay approximately million disgorgement penalty interest settlement company agree twoyear selfmonitore period report government maintain procedure ensure compliance recently issue accounting standard recently issue accounting standard refer item financial statementsnote accounting policiesrecently issue accounting standard bristolmyer squibb critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain market occur delivery product customer defer approximately million invoice daklinza early access program france portion recognize revenue final pricing obtain revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience alliance arrangement involve delivery element undelivered element evaluate qualify separate unit accounting consideration fix determinable allocate undelivered element recognize related good service deliver limited consideration contingent future deliverable consideration associate contingent milestone royalty allocate underlie element amount determined payable bms grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source refer total revenue discussion analysis significant category grosstonet sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount center medicare medicaid services medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability annual report rebate return discount adjustment grosstonet sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss exclusivity estimate product return present liability estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance insufficient historical experience product similar therapeutic area distribution method characteristic available typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis party information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citi pension discount curve plan present value benefit obligation december pension plan determine discount rate assume discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer item financial statementsnote pension postretirement postemployment liability bristolmyers squibb business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest compound development phase commercial product involve example evaluate acquisition cormorant padlock cardioxyl flexus ipierian conclude significant process transfer transaction account asset acquisition result amount allocate lead investigational compound expense capitalize addition contingent consideration potential development regulatory approval salesbase milestone sale base royalty include purchase price refer item financial statementsnote acquisition divestiture discussion acquisition similarly evaluate divestiture investigational hiv medicine business business comprise alliance reckitt erbitux ixempra business comprise alliance medicine company valeant pharmaceuticals international inc diabetes business astrazeneca conclude necessary input process transfer consequently transaction account sale business result allocation goodwill million million million carrying value business determine gain sale contingent proceed related divestiture recognize realize valuation process require certain multiple element arrangement include determination judgmental complex matter discuss example bms purchase warrant give bms exclusive right acquire promedior require determination well estimate selling price separate element identify transaction warrant clinical development service similarly divestiture diabete business astrazeneca require determination well estimate selling price element include business supply development agreement include appropriate markup estimate fair value manufacture facility refer item financial statementsnote alliance discussion transaction impairment intangible asset include iprd intangible asset billion december include license million million allocate unapproved product develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize million charge bms phase development treatment ipf million include million charge peginterferon lambda phase iii development treatment hcv discussion iprd impairment refer item financial statementsnote goodwill intangible asset annual report property plant equipment property plant equipment test impairment current fact circumstance require review include likely asset dispose prior estimate remain useful life additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation relate charge certain manufacturing facility million million million additional charge continue occur result company restructuring action announce fourth quarter contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration million valuation allowance establish item december assured believe likely defer tax asset value realize taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value bristolmyer squibb addition negative basis ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know example additional reserve million establish certain transfer pricing matter relate period discussion income taxis refer item financial statementsnote accounting policiesincome taxis note income taxis product pipeline development program manage portfolio basis early discovery latestage development include balance early stage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year individual investigational compound market product represent expense year opdivo latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product late stage pipeline product indication date development december jmhlw manufacturing marketing approval treatment relapse refractory chl receive alliance partner ono december bms seattle genetics inc announce result phase iii study evaluate adcetris brentuximab combination opdivo relapse refractory chl november approval treatment adult patient relapse refractory chl asct treatment brentuximab vedotin chl announce new result checkmate phase trial evaluate opdivo patient october chl include patient receive brentuximab vedotin andor auto hsct announce result checkmate phase trial evaluate opdivo patient june chl opdivo fda approval treatment patient chl relapse progress autohsct posttransplantation brentuximab vedotin announce result ono phase iii trial evaluate opdivo patient unresectable advanced recurrent gastric cancer refractory intolerant standard january therapy november announcement state study meet primary endpoint gastric cancer ono alliance partner conduct trial december bms alliance partner ono submit supplemental application opdivo treatment unresectable advanced recurrent gastric cancer announce extended followup datum phase trial evaluate opdivo april heavily pretreate advanced melanoma patient melanoma fda expand use opdivo single agent include previously untreated braf january mutation positive advanced melanoma patient annual report product indication date development fda approval treatment patient previously treat locally advanced muc february type bladder cancer announce result checkmate phase trial evaluate opdivo platinum october refractory patient muc muc announce ema validate company type variation application seek september extend current indication include treatment locally advanced muc adult failure prior platinumcontaine therapy announce datum checkmate phase iii trial evaluate opdivo patient june muc platinumbase therapy announce update result phase iii trial checkmate checkmate october evaluate opdivo previously treat metastatic nsclc patient present final primary analysis checkmate phase iii trial evaluate opdivo firstline monotherapy patient advance nsclc tumor express october nsclc line result disclose august show checkmate meet primary endpoint superior pfs announce datum phase iii trial checkmate checkmate evaluating opdivo versus docetaxel previously treat metastatic nsclc opdivo april approval treatment previously treat patient metastatic nsq nsclc jmhlw manufacturing marketing approval treatment unresectable august metastatic rcc receive alliance partner ono announce longterm result doserange study phase study rcc june phase study evaluate opdivo patient previously treat advanced rcc april approval treatment previously treat patient advance rcc november fda approval treatment patient scchn disease progression platinumbase therapy announce new datum checkmate phase iii trial evaluate opdivo patient october recurrent metastatic scchn platinum therapy compare investigator choice therapy scchn ema validate japan bms alliance partner ono submit application july opdivo patient previously treat recurrent metastatic scchn announce datum checkmate phase iii trial evaluate opdivo patient recurrent metastatic scchn platinum therapy compare investigator choice april therapy january checkmate stop early dmc concluding study meet primary endpoint announce datum checkmate phase trial evaluate opdivo colorectal cancer june combination yervoy patient previously treat metastatic colorectal cancer include msih announce result trial checkmate phase iii checkmate phase june evaluate opdivoyervoy combination regiman previously untreate advanced melanoma approval treatment unresectable metastatic melanoma regardless braf melanoma mutational status announce datum checkmate phase trial evaluate opdivoyervoy april combination regiman previously untreate advanced melanoma fda expand use treatment previously untreated unresectable metastatic january opdivoyervoy melanoma regardless braf mutational status announce additional result checkmate phase iii trial investigate november muc combination schedule opdivoyervoy patient locally advance muc previously treat platinumbase therapy announce update finding checkmate phase trial evaluate opdivo december nsclc monotherapy combination yervoy patient chemotherapynave advanced nsclc datum previously announce june announce update result checkmate phase trial evaluate opdivo rcc october yervoy combination regiman previously treat treatmentnave patient metastatic rcc december announce update result checkmate phase iii trial evaluate opdivo sclc monotherapy combination yervoy previously treat sclc patient bristolmyer squibb product indication date development september jmhlw manufacturing marketing approval combination revlimid lenalidomide dexamethasone treatment multiple myeloma empliciti multiple myeloma approval treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy announce new datum phase iii trial evaluate yervoy stage iii yervoy melanoma october melanoma patient high risk recurrence follow complete surgical resection september approval combination mtx treatment highly active progressive disease adult patient previously treat mtx announce commercial launch orencia clickject autoinjector new self july orencia administer autoinjector adult moderate severe present finding observational study explore moderate severe june patient response treatment base baseline status biomarker poor prognosis anticcp december jmhlw manufacturing marketing approval ximency combination tablet contain daclatasvir asunaprevir beclabuvir treatment hcv genotype fda approval daklinza use sofosbuvir treatment chronic hcv february hepatitis genotype additional patient population hcv portfolio announce result complete alloral chronic hcv regimen daklinza february combination asunaprevir phase iii trial include chinese patient population approval daklinza use sofosbuvir treatment chronic hcv january new patient population approval reyataz oral powder indicate hivinfecte child month reyataz hiv june optimize reyataz capsule pediatric dose recommendation special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event annual report quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statementsnote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge forward start interest rate swap contract designate cash flow hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt forward start swap contract manage interest rate future debt issuance estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million decrease basis point shortterm longterm interest rate decrease fair value forward start interest rate swap contract million reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt investment portfolio approximately million credit risk material certain european governmentbacke entity high risk default greece portugal italy spain monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis monitor investment counterpartie objective minimize concentration credit risk investment policy establishe limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statementsnote financial instrument fair value measurement bristolmyer squibb consolidate statement earning dollar share million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development incomeexpense total expense earning income taxis provision income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive loss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement annual report consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing current portion longterm debt account payable accrue liability defer income income taxis payable total current liability defer income income taxis payable pension liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty net asset acquisition charge adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash provide byused investing activity cash flow financing activity shortterm borrowing net issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement annual report note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end annual report term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate judgment preparation financial statement requires use management estimate judgment assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis estimate selling price multiple element arrangement determine acquisition divestiture business asset pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation reclassification provide concise financial statement presentation additional information disclose note material prior presentation current presentation consolidate include marketing sell administrative advertising product promotion statement earning expense asset heldforsale include prepay expense accrue expense consolidate balance accrue rebate return combine accrue liability sheet dividend payable pension postretirement postemployment liability combine pension liability liabilitie net earning attributable noncontrolle interest include adjustment consolidate statement divestiture gain royalty include adjustment divestiture gain royalty cash flow asset acquisition charge include adjustment asset acquisition charge revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty recognize thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance revenue reduce time recognition expect sale return discount rebate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation revenue defer historical experience product similar therapeutic category similar operational characteristic right return long exist sufficient historical experience estimate sale return develop bristolmyer squibb income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software annual report acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost include marketing sell administrative expense million million million advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci bristolmyer squibb research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide licensing right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement upfront contingent milestone payment asset acquisition investigational compound include research development expense cash flow upfront contingent milestone payment license investigational compound include operating activity asset business acquisition include investing activity divestiture proceed include investing activity royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty research development asset acquisition charge gain loss debt redemption change fair value write option liability recently issue accounting standard fasb issue new accounting standard relate revenue recognition require entity recognize revenue expect entitle transfer promise good service customer new standard subsequent amendment issued replace exist revenue recognition standard gaap effective january step model utilize achieve core principle identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfy new standard apply retrospectively prior reporting period present retrospectively cumulative effect change recognize date initial application retain earning disclosure nature time uncertainty revenue cash flow customer contract require company assessment new standard impact substantially complete base current contract currently believe timing recognize revenue typical net product sale customer significantly change new standard long require transaction price fix determinable certain variable consideration recognize prior occurrence resolution contingent event subject revenue reversal constraint result certain revenue previously defer current standard transaction price fix determinable early access program account variable consideration recognize early provide term sufficient reliably estimate ultimate price expect realize addition future royalty relate certain alliance arrangement sanofi japan erbitux arrangement disclose note alliance estimate recognize prior party sale occur provide probable estimate amount reverse future time royalty salesbase milestone form contingent consideration result divestiture business diabete north american erbitux business disclose note alliance royalty salesbase royalty licensing arrangement expect change new standard guidance pertaining separation licensing right relate fee recognition expected significantly change timing recognize revenue exist alliance arrangement currently generate revenue company currently anticipates adopt new standard modify retrospective basis cumulative effect change reflect retain earning january restate prior period result certain future royalty discuss estimate present cumulative effect accounting change exclude result operation begin subsequent significant revision estimate amount variable consideration pertain similar arrangement enter subsequent adoption new standard need estimate account comparable manner initial estimate reflect revenue assess subsequent reporting period significant change business process system control currently expect require january fasb issue amend guidance recognition measurement presentation disclosure financial instrument effective january early adoption permit new guidance require fair value adjustment equity security readily determinable fair value currently classify availableforsale report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value charge earning impairment exist company expect amend standard material impact company result operation annual report february fasb issue amend guidance lease accounting amend guidance require recognition right ofuse asset lease liability initially measure present value future lease payment lease term long month guidance effective begin early adoption permit modify retrospective approach company assessment amend standard complete minimal impact result operation expect undiscounted value lease obligation approximately million december consist primarily facility lease account operating lease initial rightofuse asset lease liability reflect adoption subject factor include actual lease portfolio early date initial application selection appropriate discount rate determine individual fix lease payment term include renewal period reasonably certain occur march fasb issue amend guidance sharebase payment transaction excess tax benefit deficiency recognize consolidated statement earning capital excess par value stock prospective basis policy election available account forfeiture occur cumulative effect change recognize adjustment retain earning date adoption excess tax benefit consolidated statement cash flow present operating activity prospective retrospective application cash payment tax authority connection share withhold statutory tax withholding requirement present financing activity retrospective application guidance effective beginning expect reduction income tax expense excess tax benefit expect material company continue current practice relate accounting forfeiture cash flow presentation change discuss increase net cash provide operating activity net cash financing activity million million june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective begin early adoption permit modify retrospective approach company expect amend standard material impact company result operation october fasb issue amend guidance income tax accounting intraentity transfer asset inventory amend guidance require tax consequence transfer asset member consolidate group recognize period transfer take place exclude inventory guidance effective begin early adoption permit quarter modify retrospective approach company early adopt amend standard begin quarter result prepay receivables defer tax asset attribute internal intellectual property transfer approximately billion reduce cumulative effect accounting change retain earning long amortize component income taxis million year addition tax impact future internal transfer intellectual property include income tax expense transfer amortize subsequent period january fasb issue amend guidance revise definition business amendment provide initial screen substantially fair value gross asset acquire disposed concentrated single identifiable asset group similar identifiable asset asset represent business consider business input substantive process significantly contribute ability create output business output need organized workforce amendment narrow definition term output guidance effective begin early adoption permit prospectively company assess potential impact amend standard january fasb issue amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative impairment test result impairment charge require report unit carry exceed fair value allocate goodwill guidance effective prospective basis early adoption permit interim annual goodwill impairment test perform january company expect amend standard material impact company result operation bristolmyer squibb note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc select geographic area information follow revenue property plant equipment dollar millions united states europe rest worlda otherb total include japan represent total revenue respectively revenue include royalty alliancerelate revenue product sell regional commercial organization product revenue follow year end december dollar million oncology empliciti elotuzumab erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab cardiovascular eliquis apixaban immunoscience orencia abatacept virology baraclude entecavir hepatitis franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise neuroscience abilify aripiprazole mature product total revenue annual report composition total revenue follow year end december dollar million net product sale alliance revenues revenues total revenue note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner product empliciti erbitux opdivo sprycel yervoy eliquis orencia sustiva atripla abilify product comprise diabetes alliance discuss certain mature brand include alliance arrangement payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income earn bristolmyers squibb equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development incomeexpense noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone licensing proceed revenue deferral attribute atripla undelivered element diabete business divestiture proceed amortization defer income primarily relate alliance million million million upfront payment new licensing alliance agreement include option license acquire related asset charge research development expense million million million specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale end customer company determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize life relate product annual report bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense amortization defer income select alliance cash flow information defer income select alliance balance sheet information december dollar millions defer income gilead bms gilead joint venture canada europe develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finishing atripla joint venture gilead sell distribute atripla principal end customer product sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell thirdparty customer europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expire allow market exclusivity atripla agreement terminate gilead launch generic version sustiva bms launch generic version truvada individual component loss exclusivity sustiva expect december event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement bristolmyers squibb summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income otsuka bms worldwide commercialization agreement otsuka codevelop copromote abilify exclude certain asian country portion agreement expire april agreement expire country june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka responsible provide sale force effort effective january bms responsible certain operating expense annual limit bms purchase api otsuka complete manufacture product subsequent sale thirdparty customer certain country otsuka assume responsibility provide funding sale force effort effective april bms provide certain service include distribution customer management pharmacovigilance bms principal end customer product sale exclusive distributor exclusive right sell abilify otsuka principal end customer product sale alliance revenue include bmss share total net sale thirdparty customer territory assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale year end bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract bmss contractual share thirdparty net sale countrie alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer bms otsuka alliance sprycel japan oncology territory party copromote product february copromotion agreement otsuka terminate japan party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale ixempra ixabepilone include alliance prior bms divestiture business fee pay otsuka base follow percentage combine annual net sale sprycel ixempra oncology territory include post divestiture ixempra sale net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million annual report summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty cost product supply include amortization extension payment reduction alliance revenue million million lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan party actively participate joint executive committee operating committee share responsibility research development resource infrastructure lilly manufacture bulk requirement erbitux facility filling finish perform party bms oversight responsibility bm exclusive distribution right north america responsible promotional effort north america lilly right copromote expense bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly bmss right obligation respect commercialization erbitux north america expired september october bms transfer right erbitux north america lilly exchange salesbase royalty describe transfer right include limited commercialization manufacturing responsibility transaction account business divestiture result noncash charge million intangible asset directly relate business allocation goodwill bms receive royalty september include income earn royalty rate applicable north america erbitux net sale million million million million plus net sale excess amount respective year royalty earn million million bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly bm transfer cocommercialization right japan merck kgaa exchange salesbase royalty include income earn royalty earn million million bristolmyer squibb summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply incomeexpense royalty divestiture loss astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide development commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale substantially country alliance agreement right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year myalept estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance prior termination alliance bms receive nonrefundable upfront milestone licensing payment million relate onglyza million relate farxiga amortization onglyza farxiga deferred income include income onglyza farxiga commercial product commencement alliance party share commercialization development expense equally profit loss annual report february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product include active product ingredient onglyza farxiga perform ongoing development activity certain clinical trial program substantially provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer mount vernon indiana manufacturing facility transfer activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration billion account include royalty million contingent regulatory milestone payment relate approval farxiga japan approximately billion consideration allocate sale business remain million allocate undelivered element describe consideration include million earn royalty include million allocate element deliver gain sale diabete business million include million quarter result primarily transfer china diabete business astrazeneca gain base difference consideration allocate sale business exclude royalty net transaction fee carry value diabete business net asset include million allocation goodwill reversal million net defer tax liability attribute amylin consideration million receive transfer mount vernon indiana manufacturing facility relate inventory result gain million amount allocate deliver element consideration allocate development supply agreement amortize applicable service period amortization defer income attribute development agreement include income sale service consider bmss ongoing major central operation revenue attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement september bm transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib royalty present income million bristolmyer squibb summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing cost reimbursement astrazeneca incomeexpense amortization defer income royalty transitional service divestiture gain select alliance cash flow information defer income divestiture proceed select alliance balance sheet information december dollar millions defer income service perform astrazeneca sanofi bms sanofi codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico bms operating partner control interest exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million million royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate alliance revenue attribute supply irbesartan api sanofi million million supply arrangement irbesartan expire annual report summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi equity net income affiliate noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment territory worldwide japan south korea taiwan ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate net sale north america applicable territory subject customary adjustment alliance arrangement include collaboration activity japan south korea taiwan pertain opdivo yervoy bms investigational compound party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer record cost product sell bristolmyer squibb summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenues abbvie bms abbvie alliance empliciti humanize monoclonal antibody treatment multiple myeloma term alliance bms grant exclusive global right codevelop commercialize empliciti pdl biopharma inc abbvie abbvie currently participate joint development commercialization committee bms final decision make authority party codevelope product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity alliance principal end customer product sale abbvie share profit loss pay tiere royalty net sale empliciti outside bms pay abbvie million certain regulatory milestone event include million approval milestone december abbvie entitle receive additional milestone payment bms certain regulatory event occur million sale threshold achieve million agreement terminate bms party material breach party subsequent notice period summarize financial information relate alliance follow year end december dollar millions revenues abbvie alliance net product sale fstar october bms enter agreement fstar agreement provide bms exclusive option purchase fstar phase ready lead asset target therapy development treatment breast gastric cancer define population herpositive patient bms pay million fstar shareholder consideration option grant certain licensing right include research development expense responsible conducting funding development option exercisable bms discretion expire early day follow obtain proof concept june additional million payable exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payment europe bms obligate provide additional financial support fstar fstar determine business define asc business combination result contingent consideration include purchase price goodwill recognize fstar variable interest entity equity holder lack characteristic control financial interest bms determine primary beneficiary power direct activity significantly directly impact economic performance entity option right describe consolidation noncontrolle interest credit million reflect fair value iprd asset million defer tax liability annual report promedior september bms purchase warrant give bms exclusive right acquire promedior biotechnology company lead asset prm develop treatment ipf warrant exercisable completion ipf phase clinical study conduct promedior expect occur early upfront payment allocate warrant million include expense remain million million upfront payment allocate promedior obligation complete phase study amortize expect period phase study allocation determine level input follow bms review phase clinical study result bms elect exercise warrant obligate pay additional million base ipf study result million base study result plus additional aggregate consideration million contingent development regulatory approval milestone payment europe prime november bms prime enter exclusive worldwide licensing collaboration agreement development commercialization prime csfr antibody program include cabiralizumab fpa currently phase iii development immunology oncology indication bms responsible development manufacturing commercialization cabiralizumab subject prime option conduct certain study cost develop cabiralizumab pvns combination internal oncology pipeline asset prime retain option copromote agreement replace previous clinical collaboration agreement party consideration licensing right bms upfront payment million include expense bms commit pay billion achievement contingent development regulatory milestone future royalty product approve commercialize reckitt bms reckitt start threeyear alliance otc product sell primarily mexico brazil reckitt receive right sell distribute market product bms receive royalty net sale product exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include marketing authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product framework alliance bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine primarily base multiple sale april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance related employee july reckitt notify bms exercise option bms sell business million refer note acquisition divestiture information nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability bms recognize income million decrease fair value option zero strengthen dollar local currency allocate right transfer reckitt amortize alliance revenue contractual term bristolmyer squibb summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information change operate asset liability divestiture proceed select alliance balance sheet information december dollar millions defer income medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc medicine company receive right sell distribute market recothrom global basis year bms exclusively supply recothrom medicine company cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option million december determine level input include accrue expense allocate right transfer medicine company amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue medicines company alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information divestiture proceed annual report valeant october bms pharmaswis whollyowne subsidiary valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december bms exclusively supply product valeant cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option acquire business million january nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense million charge include expense increase fair value option million allocate right transfer valeant amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue valeant alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information change operate asset liability divestiture proceed note acquisition divestiture acquisition acquisition evaluate determine business asset group asset follow transaction account asset acquisition determined business term define asc business combination primarily significant process acquire result amount allocate lead investigational compound expense capitalize consideration transaction allocate follow defer tax contingent dollar million year upfront payment expense assetsa consideration cormorant padlock cardioxyl flexusb ipierian relate net operating loss tax credit carryforward include million acquisition cost cormorant july bms acquire outstanding share cormorant private pharmaceutical company focus development therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary immunooncology mechanism action tcell direct antibodie costimulatory molecule contingent consideration include development regulatory milestone payment bristolmyers squibb padlock april bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patient rheumatoid arthritis padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease contingent consideration include development regulatory milestone payment cardioxyl december bms acquire outstanding share cardioxyl private biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure contingent consideration include development regulatory salesbase milestone payment flexus april bms acquire outstanding share flexus private biotechnology company focus discovery development novel anticancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include ido selective idotdo dual tdoselective compound contingent consideration include development regulatory milestone payment million milestone achieve pay shareowner flexus commencement phase clinical trial include expense ipierian april bms acquire outstanding share ipierian private biotechnology company focus new treatment tauopathies class neurodegenerative disease acquisition provide bms right ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathie contingent consideration include development regulatory milestone payment future royalty net sale acquire preclinical asset approve commercialize divestiture proceedsa divestiture gain loss royaltie dollar millions investigational hiv medicine otc product reckitt diabetes erbitux recothrom mature brand product valeant ixempra include royalty receive subsequent relate sale asset business viiv healthcare february bms sell investigational hiv medicine business viiv healthcare include number program different stage discovery preclinical clinical development transaction exclude bms hiv market medicine bms earn transitional fee million certain service february bms receive upfront payment million bm receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty product approve commercialize divestiture refer note alliance discussion divestiture transaction reckitt lilly medicines company valeant astrazeneca revenue pretax earning relate business material exclude divestiture gain annual report asset heldforsale asset heldforsale million december include prepay expense consist primarily goodwill relate investigational hiv medicine business business comprise alliance reckitt allocation goodwill determine relative fair value applicable business company reporting unit revenue pretax earning relate business material exclude divestiture gain note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension charge intangible asset impairment equity investment impairment write option adjustment loss debt redemption incomeexpense litigation settlement include million contractual dispute relate license transition service fee relate divestiture diabete investigational hiv business diabete business write option adjustment include change fair value write option liability attribute reckitt alliance valeant reckitt debt redemption loss million result early redemption euro note tender offer certain debt security include unrealized foreign exchange loss million result remeasurement bolivar denominate cash monetary balance bmss whollyowne subsidiary venezuela december exchange rate change simadi rate official cencoex rate consider limited foreign currency exchange second half publish exchange rate continue deterioration economic condition venezuela note restructuring october company announce restructure evolve streamline operating model expect incur charge connection employee workforce reduction early site exit charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation property plant equipment impairment longlive asset site shutdown cost cash outlay connection action expect approximately total charge charge approximately million recognize action fourth quarter primarily result certain employee workforce reduction accelerate depreciation expect early site exit restructuring charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market restructure charge recognize prior action primarily relate specialty care transformation initiative design create simplify organization function geographic market addition accelerate depreciation charge incur connection early exit manufacturing site ireland site employee termination benefit cost incur manufacturing sell administrative employee workforce reduction geographic region approximately bristolmyer squibb follow table summarize charge activity relate restructuring action year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell research development incomeexpense total charge year end december dollar million liability january charge change estimate provision restructure foreign currency translation spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision annual report effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate foreign tax effect certain operation ireland puerto rico switzerland tax effect capital loss federal valuation allowance release federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign effective tax rate low statutory rate primarily attributable undistributed earning certain foreign subsidiary consider expect indefinitely reinveste offshore taxis provide approximately billion undistributed earning foreign subsidiary december undistribute earning primarily relate operation switzerland ireland puerto rico undistribute earning repatriate future determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide bms operate favorable tax grant puerto rico schedule expire prior divestiture certain business result capital loss tax benefit include million sale amylin share valuation allowance attribute capital loss carryforward release follow divestiture recothrom ixempra mature brand additional reserve million establish certain transfer pricing matter related tax period orphan drug credit include federal research base credit period present goodwill allocate business divestiture include diabetes business deductible tax purpose brand prescription drug fee period charge result primarily milestone payment shareholder flexus acquisition padlock cormorant flexus cardioxyl ipierian deductible tax purpose puerto rico imposes excise tax gross company purchase price good sell manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize provision income taxis excise tax incur increase manufacturing activity opdivo result high domestic manufacturing deduction bristolmyer squibb defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward capital loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis noncurrent income taxis payable noncurrent total internal transfer intellectual property result defer tax asset include prepay taxis million december million prepay taxis december asset amortize expect life refer recently issue accounting standard note accounting policy information impact amend guidance company expect adopt federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal defer tax asset annual report change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority include limited major tax jurisdiction list table propose consider propose material adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction bristolmyer squibb follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial asset liability december annual report financial asset liability measure fair value recur basis summarize december december dollar million level level level level cash cash equivalent money market security marketable security certificate deposit commercial paper corporate debt security equity fund fix income fund derivative asset equity investment derivative liability availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit commercial paper corporate debt security equity investment total december certificate deposit corporate debt security equity investment total december december dollars million current marketable securitiesa noncurrent marketable securitiesb asset total fair value option financial asset elect investment equity fix income fund fair value investment million december million december include current marketable security change fair value significant noncurrent marketable security mature year december bristolmyers squibb qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract prepaid expense interest rate swap contract asset interest rate swap contract accrue liability interest rate swap contract pension liability forward start interest rate swap contract prepaid expense forward start interest rate swap contract asset forward start interest rate swap contract accrue liability forward start interest rate swap contract pension liability foreign currency forward contract prepay expense foreign currency forward contract accrue liability derivative designate hedge instrument foreign currency forward contract prepay expense foreign currency forward contract accrue liability foreign currency forward contract pension liability cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase transaction certain foreign currency transaction effective portion change fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain foreign currency forward contract expect reclassify net earning primarily include cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december bm enter million forward start interest rate swap contract mature march hedge variability probable forecast interest expense associate potential future issuance debt contract designate cash flow hedge effective portion fair value change include comprehensive income earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis net investment hedge nonus dollar borrowing million million december designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain remeasurement euro debt million million million respectively record foreign currency translation component accumulate comprehensive loss relate offset longterm debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million million notional fixedtofloate interest rate swap contract terminate million million million generating proceed million million million include accrue interest additional contract terminate connection debt redemption annual report debt obligation shortterm borrowing current portion longterm debt include december dollar millions bank draft shortterm borrowing current portion longterm debt total average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december commercial paper borrowing longterm debt current portion longterm debt include december dollar million principal value note note note note note euro note note euro note note note note note note mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost total current portion longterm debt longterm debt fair value longterm debt million million december respectively estimate level input base quote market price similar debt instrument fair value short term borrowing approximate carry value short maturity debt instrument bristolmyer squibb senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price bms terminate forward start interest rate swap contract enter result unrealized loss comprehensive income follow table summarize issuance longterm debt obligation amount million euro dollar principal value euro note euro note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional unrealize loss follow summarize debt redemption activity dollar million principal carry value debt redemption price notional interest rate swap contract terminate interest rate swap termination payment loss debt redemptiona include acceleration debt issuance cost loss interest rate lock contract relate fee interest payment million million million net amount receive interest rate swap contract currently separate billion revolving credit facility syndicate lender facility provide customary term condition financial covenant extend october july facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december available financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund annual report note receivable december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance receivables prepay refundable income taxis receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory asset asset include inventory pende regulatory approval million december million december amount expect remain onhand year bristolmyer squibb note property plant equipment lease december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million million sublease income capital lease obligation material period present note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year iprd gross intangible asset accumulate amortization total intangible asset amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million million million iprd impairment charge recognize bms lpa antagonist phase development treatment ipf writeoff require consider occurrence certain adverse event voluntary suspension study internal assessment indicate significantly low likelihood regulatory commercial success bms acquire bms acquisition amira pharmaceuticals inc addition contingent consideration liability million relate acquisition reverse low likelihood success million iprd impairment charge recognize peginterferon lambda phase iii development treatment hcv writeoff require assess potential commercial viability asset estimate fair value assessment consider low likelihood file registration certain market complete revise projection revenue expense significant decline prior project revenue result global introduction oral noninterferon product treat patient hcv alternative use product annual report note accrue liability december dollars millions accrue rebate return employee compensation benefit accrue research development dividend payable royalty brand prescription drug fee restructure pension postretirement benefit litigation settlement total accrue liability note equity common stock capital accumulate treasury stock excess par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january net earning comprehensive loss cash dividend stock compensation debt conversion variable interest entity distribution balance december net earning comprehensive loss cash dividend stock compensation debt conversion distribution balance december net earning comprehensive loss cash dividend stock repurchase program stock compensation distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method october board director approve new share repurchase program authorize repurchase additional billion common stock repurchase open market private transaction include repurchase plan establish accordance rule securities exchange act stock repurchase program expiration date suspend discontinue time bristolmyer squibb february bms enter asr agreement goldman sachs morgan stanley llc repurchase approximately billion common stock aggregate asr fund combination debt cash exist share repurchase authorization total number share ultimately repurchase asr determine final settlement base discount volumeweighte average price bms common stock asr period expect complete june components comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedgesa unrealize gainslosse reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gainslosse realize gainslossesc availableforsale security foreign currency translation total comprehensive incomeloss include cost product sell include cost product sell research development marketing sell administrative expense include incomeexpense accumulate balance relate component comprehensive loss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement benefit plan bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fix income security annual report net periodic benefit costcredit define benefit pension plan include dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss curtailment settlement special termination benefit net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan enter definitive agreement transfer certain pension asset prudential settle approximately billion pension obligation bms purchase group annuity contract prudential december irrevocably assume obligation future annuity payment certain bms retiree transaction change monthly pension benefit receive affected retiree survive beneficiary result pretax settlement charge million pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow dollar million benefit obligation begin year service costbenefit earn year interest cost settlement actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize asset accrue liability pension liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively bristolmyer squibb additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation december follow discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit creditcost year end december follow discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense annual report postretirement benefit plan comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome securities postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient equity fund venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company fasb issue amend guidance remove requirement categorize fair value hierarchy investment fair value measure nav share equivalent practical expedient guidance apply retrospectively table venture capital limited partnership investment typically redeemable distribution liquidation underlie asset significant unfunded commitment investment essentially liquidation expect occur remain investment practical expedient redeemable weekly monthly basis bristolmyer squibb follow summarize activity financial asset utilize level fair value measurement dollar million insurance contract fair value january purchase sale settlement net realize loss fair value december purchase sale settlement net fair value december investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range approximately million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment number share issue performance share unit vest determine base achievement performance goal base company threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date annual report stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value award vest restricted stock unit market share unit performance share unit total intrinsic value stock option exercise fair value restrict stock unit market share unit performance share unit approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value market share unit performance share unit consider probability satisfy payout factor total shareholder return respectively bristolmyer squibb follow table summarize significant range outstanding exercisable option december option outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value range exercise price thousand life year share million aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place company apotex settle apotex case case dismiss australian government claim pende trial schedule august possible time predict outcome australian government claim impact company annual report sprycel european union apotex actavis group ptc ehf generics limited mylan unnamed company file opposition european patent office epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition division decision patent revoke orphan drug exclusivity datum exclusivity sprycel expire november epo board appeal decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat chronic myelogenous leukemia cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epo opposition division revoke october company intend appropriate legal action protect sprycel experience decline european revenue event generic dasatinib product enter market antipd antibody patent opposition litigation january bms ono announce company sign global patent license agreement merck settle patentinfringement litigation relate merck antibody keytruda pembrolizumab agreement result dismissal prejudice patent litigation company pertain keytruda bms ono assert litigation merck sale keytruda infringe company patent relate use antibody treat cancer europe netherlands france germany ireland spain switzerland australia japan agreement merck initial payment million bms ono merck obligate pay ongoing royalty global sales keytruda january december january december agreement company grant certain right respective patent portfolio pertain initial payment royalty share bms ono percent allocation respectively adjust party incur legal fee september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent direct method treat cancer antibody specifically danafarber seeking add scientist inventor patent price sale promotional practice litigation plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation mdl coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company bristolmyer squibb byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp plaintiffs mdl appeal court appeal ninth circuit jccp plaintiff appeal california court appeal amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company abilify company otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder approximately case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose united states district court northern district florida eliquis company pfizer codefendant product liability litigation relate eliquis plaintiff assert claim include claim wrongful death result bleed allege cause use eliquis case file state federal court unite states case file canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose united states district court southern district new york shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement securities exchange commission allege foreign corrupt practice act violation china company agree payment approximately million disgorgement penalty interest company file motion dismiss shareholder derivative lawsuit government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation significant investigation conduct government agency company aware list abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition coalition investigate certain abilify marketing practice violate respective state consumer protection statute company executive committee coalition reach settlement matter state new mexico member coalition participate settlement consent decree enter participate state december environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party annual report cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party million include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earning attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset longterm debt include current portion bristolmyer squibb follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment incomeexpense increasedecrease pretax income income tax item increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrativeb license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gainslosse pension charge intangible asset impairment write option adjustment loss debt redemption incomeexpense increasedecrease pretax income income tax item increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost specify item marketing sell administrative process standardization implementation cost annual report report management management responsibility financial statement management responsible preparation integrity financial information present annual report accompany consolidated financial statement prepare conformity united states generally accept accounting principle apply certain estimate judgment require management opinion consolidated financial statement present fairly company financial position result operation cash flow audit committee board director meet regularly internal auditor deloitte touche llp company independent register accounting firm management review account internal control structure financial reporting matter internal auditor free access audit committee set forth company standard business conduct ethic company firmly commit adhere high standard moral ethical behavior business activity management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include giovanni caforio chief executive officer charle bancroft chief financial officer february bristolmyers squibb control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting information annual report report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting parsippany new jersey february bristolmyers squibb report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement parsippany new jersey february annual report performance graph follow performance graph compare performance bristolmyer squibb period indicate performance standard poor stock index average performance group consist peer corporation line ofbusiness basis corporation make peer group abbvie inc amgen inc astrazeneca plc biogen inc celgene corp eli lilly company gilead sciences inc glaxosmithkline johnson johnson merck inc novartis pfizer inc roche holding ltd sanofi total return index reflect reinveste dividend weight beginningperiod market capitalization report time period bristolmyers squibb index peer group assume invest bristolmyer squibb common stock index peer group value december specify year assume dividend reinveste bristolmyer squibb fiveyear financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtb equity discussion item affect comparability result year refer item management discussion analysis financial condition result operationsnongaap financial measure include current noncurrent portion annual report summary abbreviate term bristolmyer squibb company refer bristolmyer squibb bms company annual report annual report term define annual report fiscal year end december lilly eli lilly company abbvie abbvie inc maa marketing authorization application amira amira pharmaceuticals inc mcos manage care organization amylin amylin pharmaceuticals inc mcrc metastatic colorectal cancer anda abbreviate new drug application mead johnson mead johnson nutrition company anticcp anticyclic citrullinate peptide acpa medarex medarex inc api active pharmaceutical ingredient merck merck inc asct autologous stem cell transplant myelofibrosis asr accelerate share repurchase msih high microsatellite instability astrazeneca astrazeneca plc mtx methotrexate autohsct autologous hematopoietic stem cell transplantation muc metastatic urothelial carcinoma bla biologics license application nav net asset value cardioxyl cardioxyl pharmaceuticals inc nda new drug application cdai clinical disease activity index nitto denko nitto denko corporation cercla comprehensive environmental response compensation liability act nkt natural killer cell cgmp current good manufacturing practice novartis novartis pharmaceutical corporation chl classical hodgkin lymphoma nsclc nonsmall cell lung cancer chmp committee medicinal product human use nsq nonsquamous cormorant cormorant pharmaceutical nvaf nonvalvular atrial fibrillation cppib cppib credit europe sarl luxembourg private limited liability company oci comprehensive income office inspector general dept health csfr colony stimulate factor receptor oig human services dmc datum monitor committee ono ono pharmaceutical ltd ebitda earning interest taxis depreciation amortization orr objective response rate european commission otc overthecounter egfr epidermal growth factor receptor otsuka otsuka pharmaceutical ltd ela excess loss account pad proteinpeptidyl arginine deiminase ema european medicine agency padlock padlock therapeutics inc epo european patent office pbms pharmacy benefit manager ep earning share program death receptor erisa employee retirement income security act pdma prescription drug marketing act european union pfizer pfizer inc fasb financial accounting standard board pfs progressionfree survival fcpa foreign corrupt practice act portola portola pharmaceuticals inc fda food drug administration promedior promedior inc prime prime therapeutics inc prp potentially responsible party flexus flexus biosciences inc prudential prudential insurance company america fstar fstar alpha ltd psa prostatespecific antigen gaap generally accept accounting principle pvns pigment vilonodular synovitis gdd genetically define disease research development gilead gilead sciences inc rheumatoid arthritis hcv hepatitis virus ravs resistanceassociate variants hiv human immunodeficiency virus rcc renal cell carcinoma hazard ratio reckitt reckitt benckiser group plc patient protection affordable care act rheumatoid factor hsp heat shock protein scchn squamous cell carcinoma head neck ima inventory management agreement sclc small cell lung cancer imclone imclone system incorporate sec securities exchange commission immunooncology squamous inhibitex inhibitex inc svr sustain virologic response ipf idiopathic pulmonary fibrosis plan stock award incentive plan ipierian ipierian inc united states iprd inprocess research development united kingdom jmhlw japanese ministry health labour welfare valeant valeant pharmaceuticals international inc lda low disease activity vte venous thromboembolic libor london interbank offer rate wto world trade organization bristolmyers squibb board director lamberto andreotti alan lacy chairman board directors nonexecutive chairman bristolmyers squibb dave busters entertainment inc giovanni caforio chief executive officer chairmandesignate thomas lynch bristolmyers squibb chairman chief executive officer massachusetts general physicians organization peter arduini president chief executive officer integra lifescience holdings corporation dinesh paliwal chairman president chief executive officer harman international industries inc robert bertolini president chief financial officer bausch lomb theodore samuel retire president capital guardian trust company matthew emmens retire chief executive officer chairman vicki sato phd shire plc professor management practice harvard business school laurie glimcher president ceo danafarber cancer institute principal investigator director danafarber gerald storch harvard cancer center richard susan smith chief executive officer hudson bay company professor medicine harvard medical school nonexecutive chairman supervalu inc michael grobstein togo west retired vice chairman ernst young llp chairman tli leadership group members board director march member elect annual meeting audit committee committee director corporate governance compensation management development committee science technology committee bristolmyer squibb leadership team giovanni caforio ann powell judge chief executive officer senior vice president chief human resource officer charle bancroft executive vice president chief financial officer sandra leung head global business operation executive vice president general counsel emmanuel blin senior vice president chief strategy officer anne nielsen senior vice president chief compliance ethic officer francis cuss bchir frcp executive vice president chief scientific officer lou schmukler president global manufacturing supply john elicker senior vice president public affairs investor relation paul von autenrie senior vice president chief information officer murdo gordon executive vice president chief commercial officer bristolmyer squibb stockholder information common stock product name company program ticker symbol bmy free copy company annual global product company program new york stock exchange report fiscal year name appear italic end december contact refer register annual meeting stockholder approve trademark corporate secretary specifically note tuesday bristolmyer squibb company bristolmyers squibb company park avenue abilify trademark otsuka princeton pike new york pharmaceutical ltd lawrence township available adcetris trademark seattle stockholder services investorbmscom genetics inc inquiry concern stockholder recent certification atripla trademark bristolmyer account stock transfer matter companys chief executive officer chief squibb gilead sciences llc financial officer pursuant section include address change sarbanesoxley act file avaproavalide know elimination duplicate mailing exhibit companys aprovelkarvea plavix shareowner service plus plansm company file new york trademark sanofi direct company stock exchange recent annual transfer agent registrar bydureon byetta symlin trade ceo certification require section mark amylin pharmaceuticals llc new york stock exchange wells fargo shareowner services list company manual erbitux trademark imclone llc centre pointe curve suite mendota height farxiga onglyza trademark additional information astrazeneca wwwshareowneronlinecom information follow subject gleevec trademark novartis available wwwbmscom outside bristolmyers squibb foundation ixempra trademark rpharm operate llc telecommunications relay service clinical trial hear impair compliance ethic keytruda trademark merck sharp call telephone number diversity workforce statistics dohme corp shareowner service plus plansm patient assistance program myalept trademark aegerion policy advocacy engagement pharmaceuticals inc shareowner service plus plansm political contribution design longterm investor wish prostvac trademark build share ownership company sustainabilityenvironmental programs immunotherapeutics inc common stock time partici annual report contain certain recothrom trademark pate plan register holder forwardlooke information medicine company company common stock mean private security litigation company common stock revlimid trademark celgene reform act forwardlooke participant make corporation statement base current expectation initial purchase plan plan involve inherent risk uncertaintie truvada tybost trademark feature dividend reinvestment optional cause actual outcome result gilead sciences inc andor cash purchase share safekeeping differ materially current expectation affiliate share sale transfer bristolmyer financial review squibb company appoint wells fargo brand name product discussion description shareowner service administrator italicize letter asterisk risk uncertaintie company plan plan sponsor adminis register trademark bristolmyer undertake obligation publicly update tere bristolmyer squibb company squibb andor subsidiary forwardlooke statement result new information future event shareowner service plus plan service mark wells fargo shareowner services callia baine manage physical emotional pain diagnose want tell callia rheumatoid arthritis know firsthand say want pity pain swollen stiff joint find answer ache muscle fatigue live life graduate college take yearold callia baine fulltime job human resource able live life term maryland resident continue debilitate effect gratei thl symptoms undiagnose cause emotional pain year ago casual game overshadow physical pain tugofwar dog inadvertently lead answer life recall callia begin notice symptom teenager hang play dog accidentally bite callias friend know normal thing hand morning woke discover hand swollen red went doctor rule year callia family seek medical answer dog bite cause swelling order blood experience painful foot cramp spasm work test come positive spread leg exhaust time symptom drastically limit activity high finally diagnosis bring clarity callias world school college diagnosis immediate initial treatment manage bring relief callia feel like leave deal condition hope physician prescribe orencia follow treatment callia feel like regain mobility particular episode college callia call experience pain mom cry pain foot severe know mom ask live life incredibly grateful ask friend help callia say feel like bristolmyer squibb company right reserve park avenue new york wwwbmscom facebook logo cmyk facebook logo cmyk